



Psychotic Like Experiences in Healthy Adolescents are Underpinned by Lower Fronto-Temporal Cortical Gyrification: a Study from the IMAGEN Consortium

Raka Maitra, Charlotte Horne, Owen O'daly, Evangelos Papanastasiou, Christian Gaser, Tobias Banaschewski, Gareth Barker, Arun Bokde, Sylvane Desrivieres, Herta Flor, et al.

► To cite this version:

Raka Maitra, Charlotte Horne, Owen O'daly, Evangelos Papanastasiou, Christian Gaser, et al.. Psychotic Like Experiences in Healthy Adolescents are Underpinned by Lower Fronto-Temporal Cortical Gyrification: a Study from the IMAGEN Consortium. Schizophrenia Bulletin, 2023, 49 (2), pp.309-318. 10.1093/schbul/sbac132 . hal-04542924

HAL Id: hal-04542924

<https://hal.science/hal-04542924v1>

Submitted on 17 Sep 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

Psychotic Like Experiences in Healthy Adolescents are Underpinned by Lower Fronto-Temporal Cortical Gyrification: a Study from the IMAGEN Consortium

Raka Maitra^{*,1a,†,●}, Charlotte M Horne^{1a,†}, Owen O'Daly², Evangelos Papanastasiou^{1a,1c}, Christian Gaser^{1b,1c}, IMAGEN list of authors (Tobias Banaschewski¹, Gareth J. Barker^{2,†}, Arun L. W. Bokde³, Sylvane Desrivieres⁴, Herta Flor^{5,6}, Antoine Grigis⁷, Hugh Garavan⁸, Penny Gowland^{9,●}, Andreas Heinz¹⁰, Rüdiger Brühl¹¹, Jean-Luc Martinot¹², Marie-Laure Paillère Martinot^{13,●}, Eric Artiges¹⁴, Frauke Nees^{15,15}, Dimitri Papadopoulos Orfanos⁷, Herve Lemaitre^{7,16,●}, Tomáš Paus^{17,18,●}, Luise Poustka¹⁹, Sarah Hohmann¹, Sabina Millenet¹, Juliane H. Fröhner²⁰, Lauren Robinson²¹, Michael N. Smolka²⁰, Henrik Walter¹⁰, Jeanne M. Winterer^{10,22}, Robert Whelan²³, Erin Burke Quinlan⁴, Alex Ing⁴, Gunter Schumann^{4,15,24,25}); and IMAGEN Consortium, Sukhi Shergill^{1a,1d}

^{1a}Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; ^{1b}Departments of Neurology, Jena University Hospital, Jena, Germany; ^{1c}Departments of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany; ^{1d}Kent and Medway Medical School, Canterbury, UK; ^{1e}Therapeutic Area CNS, Boehringer Ingelheim International GmbH, Ingelheim, Germany; ¹Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; ²Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; ³Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland; ⁴Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology and Neuroscience, Social, Genetic and Developmental Psychiatry Centre, King's College London, UK; ⁵Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; ⁶Department of Psychology, School of Social Sciences, University of Mannheim, Mannheim, Germany; ⁷NeuroSpin, CEA, Université Paris-Saclay, Gif-sur-Yvette, France; ⁸Departments of Psychiatry and Psychology, University of Vermont, Burlington, Vermont, USA; ⁹Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK; ¹⁰Department of Psychiatry and Psychotherapy CCM, Charité—Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; ¹¹Physikalisch-Technische Bundesanstalt (PTB), Braunschweig and Berlin, Germany; ¹²Institut National de la Santé et de la Recherche Médicale, INSERM U 1299 “Trajectoires développementales en psychiatrie”; Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli, Gif-sur-Yvette, France; ¹³Institut National de la Santé et de la Recherche Médicale, INSERM U 1299 “Trajectoires développementales en psychiatrie”, Université Paris-Saclay, Ecole Normale Supérieure Paris-Saclay, CNRS; Centre Borelli, Gif-sur-Yvette, France; and AP-HP, Sorbonne Université, Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France; ¹⁴Institut National de la Santé et de la Recherche Médicale, INSERM U 1299 “Trajectoires développementales en psychiatrie”; Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli, Gif-sur-Yvette; and Psychiatry Department, EPS Barthélémy Durand, Etampes, France; ¹⁵PONS Research Group, Dept of Psychiatry and Psychotherapy, Campus Charité Mitte, Humboldt University, Berlin, Germany; ¹⁶Institut des Maladies Neurodégénératives, UMR 5293, CNRS, CEA, Université de Bordeaux, Bordeaux, France; ¹⁷Departments of Psychiatry and Neuroscience, Faculty of Medicine and Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; ¹⁸Departments of Psychology and Psychiatry, University of Toronto, Toronto, Ontario, Canada; ¹⁹Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Centre Göttingen, Göttingen, Germany; ²⁰Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany; ²¹Department of Psychological Medicine, Section for Eating Disorders, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; ²²Department of Education and Psychology, Freie Universität Berlin, Berlin, Germany; ²³School of Psychology and Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland; ²⁴Leibniz Institute for Neurobiology, Magdeburg, Germany; ²⁵Institute for Science and Technology of Brain-inspired Intelligence (ISTBI), Fudan University, Shanghai, P.R. China

*To whom correspondence should be addressed; telephone: 0-207-848-0728; e-mail: raka.maitra@kcl.ac.uk

[†]Drs Raka Maitra and Charlotte are considered joint first authors.

Background and Hypothesis: Psychotic Like Experiences (PLEs) are widely prevalent in children and adolescents and increase the risk of developing psychosis. Cortical gyrification characterizes brain development from in utero till about the first 2 years of life and can be measured in

later years as *static gyrification* changes demonstrating neurodevelopment and *dynamic gyrification* changes reflecting brain maturation during adolescence. We hypothesized that PLEs would be associated with *static cortical gyrification* changes reflecting a neurodevelopmental

abnormality. *Study Design:* We studied 1252 adolescents recruited in the IMAGEN consortium. We used a longitudinal study design, with Magnetic Resonance Imaging measurements at age 14 years and age 19 years; measurement of PLEs using the Community Assessment of Psychic Experiences (CAPE) questionnaire at age 19 years; and clinical diagnoses at age 23 years. *Study Results:* Our results show *static gyrification* changes in adolescents with elevated PLEs on 3 items of the CAPE—voice hearing, unusual experiences of receiving messages, and persecutory ideas—with lower cortical gyrification in fronto-temporal regions in the left hemisphere. This group also demonstrated *dynamic gyrification* changes with higher cortical gyrification in right parietal cortex in late adolescence; a finding that we replicated in an independent sample of patients with first-episode psychosis. Adolescents with high PLEs were also 5.6 times more likely to transition to psychosis in adulthood by age 23 years. *Conclusions:* This is the largest study in adolescents that demonstrates fronto-temporal abnormality of cortical gyrification as a potential biomarker for vulnerability to PLEs and transition to psychosis.

Key words: cortical gyrification/adolescence/psychotic like experiences/IMAGEN/MRI/psychosis.

Introduction

Psychotic symptoms exist on a continuum, from Psychotic Like Experiences (PLE) at one end of the spectrum to clinical phenotypes such as schizophrenia at the other end. As the definition of PLEs varies,¹ here we refer to PLEs as subtle, subclinical symptoms of psychosis (ie, in otherwise healthy, nontreatment seeking individuals) that are present in the general population including perceptual disturbances, paranoid ideation, and “magical” thinking.² PLEs offer a compelling model for subclinical psychosis because they are phenomenologically similar to psychotic illness, are heritable, share common genetic influences with depression and schizophrenia,³ and overlap with other risk factors for schizophrenia such as childhood trauma, victimization, and substance use.⁴ If PLEs arise from abnormalities of brain structure that predispose to dysfunction within cognitive and perceptual networks, then detecting such structural abnormalities may help understand the mechanisms underpinning psychosis and identify individuals at risk of developing psychosis.

PLEs are common in childhood, occurring in 17% of children aged 9–12 years,⁵ and have their highest prevalence in younger adolescents (21%–23%) compared to older adolescents (7%).⁶ Presence of PLEs in children aged 11 years may be a significant predictor of schizophreniform disorder at age 26 years.⁷ A large study of 3801 young adults reported that experience of hallucinations at age 14 years, especially in the presence of childhood behavior problems, was a predictor of

delusional experiences and non-affective psychosis at age 21 years.^{8,9} Overall, adolescents with PLEs were 3.5 times more likely to transition to a clinical psychotic disorder in adulthood compared to adolescents with no PLEs¹⁰ and the association between PLEs and a diagnosable psychiatric disorder was shown to increase with age—where 57% of early adolescents (aged 11–13 years) and 80% of mid adolescents (aged 13–16 years) with reported psychotic symptoms had at least one diagnosis.⁶

Adolescence is marked by significant neurodevelopmental changes that may be reflected in structural changes in the brain. Structural brain abnormalities have been noted in adolescents experiencing PLEs^{11,12} with some of these structural changes being associated with genetic loading.^{3,13} Cortical gyrification is a developmental process that refers to the folding of the cortex into gyri and sulci. Gyrification increases rapidly in-utero until 2 years after birth and then remains relatively constant therefore offering a stable marker of neurodevelopmental changes.¹⁴ We refer to this stable type of gyrification as a result of early neurodevelopmental changes as “static” gyrification. There also may be further changes in cortical gyrification that occur later such as nonlinear decreases in gyrification¹⁵ although the processes that contribute to these later changes in gyrification are less well understood. Here we refer to this later maturational aspect of gyrification as “dynamic” gyrification. Abnormalities of gyrification may be associated with persistence of PLEs in adolescents and increased risk of developing psychosis.¹⁶

Only a handful of studies, mostly in young adults, have explored gyrification as a neurodevelopmental marker for risk of developing psychosis (see Appendix in [Supplement](#)). While the gyrification data presents a mixed picture, the main regional findings are alterations reported in the frontal, temporal, and parietal lobes, with some decreases in gyrification suggesting that an early neurodevelopmental change results in the persistence of psychotic symptoms^{16–18}; and other studies reporting higher gyrification^{19,20} as well as no changes in gyrification.^{21,22} A recent review of these gyrification findings in ultra-high risk and early psychosis populations report higher gyrification in frontal, temporal, and parietal regions while there may be more significant decreases evident in the established disease.²³ Another study suggests higher gyrification in early psychosis with less clear findings in those at high risk for psychosis.²⁴ In these cross-sectional studies, the differentiation between static and dynamic gyrification changes and their implication in psychosis remain unclear.

Our aim was to study abnormalities in static and dynamic cortical gyrification in healthy adolescents experiencing PLEs compared to those not experiencing PLEs. We measured cortical gyrification from structural magnetic resonance imaging (MRI) scans collected at baseline (14 years) and follow-up (19 years) from 1252

adolescents that participated in the IMAGEN consortium.²⁵ PLEs were assessed at follow-up (19 years) using the Community Assessment of Psychic Experiences (CAPE-42).²⁶ We also investigated whether differences in cortical gyrification associated with PLEs were relevant to clinically diagnosed psychotic symptoms by comparing cortical gyrification in an independent sample of patients with first-episode psychosis and healthy controls (HC), and assessing how many high PLE adolescents transitioned to psychosis illness at a final follow-up phase (age 23 years).

We hypothesized that:

- 1) Adolescents with PLEs, with high CAPE scores, would show a neurodevelopmental abnormality as indexed by altered frontal and temporoparietal static cortical gyrification at baseline compared to those without PLEs.
- 2) Adolescents with PLEs, with high CAPE scores, would show a neurodevelopmental abnormality as evidenced by persistently altered frontal and temporoparietal static cortical gyrification from baseline to follow-up compared to adolescents without PLEs.
- 3) Altered static cortical gyrification in adolescents with PLEs would show clinical relevance to symptoms of psychosis as indexed by a) similarly altered static cortical gyrification in an independent sample of patients with early psychosis compared to HC, and b) a higher rate of transition to psychosis at follow-up in the adolescents experiencing elevated levels of PLEs.¹⁰

Methods

Participants

A total of 1252 adolescents were selected from the IMAGEN consortium²⁵ based on availability of a complete behavioral and neuroimaging data set at ages 14 (baseline) and 19 years (follow-up) and additional behavioral data at age 23 years. Ethical approval had been obtained by the ethics research committee of the IMAGEN consortium.²⁵ Access to the IMAGEN database was obtained after approval by the IMAGEN committee and deidentified data were downloaded. The present study included participants that were recruited between January 1, 2016 and January 1, 2017.

Sample Stratification

Participants were stratified into “high” and “low” PLE groups on the basis of scores of selected items from the CAPE questionnaire as described in our previous publication.²⁶ The CAPE questionnaire is a 42-item questionnaire that has been shown to have good validity and reliability for measuring PLEs as reported in a recent

meta-analysis of 111 studies.^{27,28} Briefly, two complementary stratifications were performed. First, high and low scorers were determined based on the upper and lower quartiles of the composite scores of items-5 (bizarre experiences), 7 (perceptual abnormalities), and 33 (persecutory ideas) from the CAPE questionnaire (hereon referred to as the “CAPE-3” sample). This stratification was based on 2 studies showing these 3 factors are most important for predicting poor outcomes in adolescents experiencing PLEs^{28,29} (see [Supplementary Materials](#)). Second, the upper and lower deciles of the total CAPE scores (hereon referred to as the “CAPE-42” sample) were used to determine high and low PLE scorers.

Measures of IQ and General Psychopathology

IQ was measured using the Wechsler Intelligence Scale for Children (WISC, IV),³⁰ alcohol consumption using the Alcohol Use Disorders Identification Test (AUDIT),^{31,32} cannabis use using the Drug Abuse Screening Test (DAST),³³ and depressive symptoms using the Adolescent Depression Rating Scale (ADRS).³⁴ WISC scores were available only at baseline while CAPE, ADRS, AUDIT, and DAST scores were available only at follow-up.

MRI Acquisition

MRI data were acquired from the following participating centers for IMAGEN study: Institute of Psychiatry, University of Nottingham (UK); Charité University Berlin, Technical University Dresden, University Medical Centre Hamburg-Eppendorf, Central Institute of Mental Health Mannheim (Germany); National Institute of Health and medical Research (France); and Trinity College Dublin (Ireland) using 3T scanners from four different manufacturers namely Siemens, Philips, GE Healthcare and Bruker. A full description of the scanning protocols, cross-site standardization and quality checks, and pre-processing of resulting data are provided elsewhere.³⁵

Cortical Gyrification

The cortical surface was extracted and local gyrification was measured across the whole brain using the CAT12 toolbox (<http://dbm.neuro.uni-jena.de/cat/>) in SPM12 software (<http://www.fil.ion.ucl.ac.uk/spm>, Wellcome Trust Centre for Neuroimaging), (see [Supplementary Materials](#)). This method for calculating a local gyrification index is based on the absolute mean curvature of the brain surface and was chosen as a simple measure that is sensitive to both amplitude and frequency of the folding pattern.³⁶ CAT12 has also previously been used to explore gyrification in adults with PLEs.³⁷ To ensure normal distribution of gyrification indices, smoothing was applied using a Gaussian kernel

of 20 mm FWHM (the recommended CAT12 filter size) prior to statistical analyses. The results are displayed using the Desikan atlas.³⁸

Statistical Analysis

Demographics, measures of IQ, and general psychopathology were analyzed using SPSS.³⁹

All statistical analyses of neuroimaging data were performed using SPM12 (<http://www.fil.ion.ucl.ac.uk/spm>; Wellcome Trust Centre for Neuroimaging). A flexible factorial model was used with CAPE score grouping (ie CAPE-3 or CAPE-42) as the between-subjects factor (high and low scorers) and TIME as the within-subjects factor (baseline and follow-up visits) to explore the main effect of group, time, and the interaction between group and time.

Neuroimaging results were considered at a statistical cluster height threshold of $P < .001$ uncorrected, with the cluster extent of 50 vertices—similar to previous gyrification studies.^{40,41} Main effects reported at an uncorrected threshold were then subjected to more statistically stringent post-hoc tests using non-parametric methods such as Threshold Free Cluster Enhancement (TFCE) using a threshold of $P < .001$ and 5000 permutations.⁴²

Independent Replication Sample

To examine whether the mechanism underlying PLEs was the same as that in clinical psychosis, we performed a cross-sectional replication analysis in an independent sample of 102 medicated patients with early psychosis (duration of illness <5 years) compared to 43 HC collected as part of the MUTRIPS study.⁴³

Follow-up Diagnoses

Finally, we assessed the utility of the high and low CAPE-3 classification by examining how many adolescents in each group developed psychosis at a clinical follow-up at age 23 years. Clinical diagnoses were established using the Mini-International Neuropsychiatric Interview (M.I.N.I.).⁴⁴

Results

Demographics

Demographics for each sample stratification are available in Table 1. Briefly, for the CAPE-3 sample stratification there was a total sample of 600 adolescents with 313 high CAPE-3 scorers and 287 low CAPE-3 scorers. There were no significant differences in age, IQ (WISC IV), alcohol use (AUDIT), and cannabis use (DAST) scores between the high and low CAPE-3 scorers. Only the ADRS scores differed between the 2 groups ($Z = 9.7$, $P < .001$) where

low CAPE-3 scorers displayed higher depressive symptoms than high CAPE-3 scorers.

High Versus Low CAPE-3 Scorers

Using a flexible factorial model, there was a main effect of CAPE on (static) cortical gyrification in the banks of the left superior frontal gyrus, precentral gyrus, superior temporal sulcus, and middle temporal gyrus ($F(1,598) = 10.88$, $P < .001$). Post-hoc t -tests showed that the high scorers on the CAPE-3 had lower gyrification in these areas compared to low scorers ($t(1,598) = 3.10$, $P < .001$) (figure 1a) where effects in the left precentral gyrus and left middle temporal gyrus were the most robust ($P < .001$ TFCE). Adding gender and scanning site as covariates to the model did not provide additional findings.

There was also a main effect of TIME (ie, across the whole CAPE-3 sample) where there were changes in (dynamic) cortical gyrification at follow-up, compared to baseline, in bilateral dorsal middle frontal, superior frontal, precentral, superior parietal, inferior parietal, precuneus, insula, and lingual gyrus; right postcentral, supramarginal, superior temporal, middle temporal, and entorhinal cortex. The observed changes in cortical gyrification were statistically significant ($F(1,598) = 17.85$, FWE corrected $P < .05$) and were most marked in prefrontal areas (figure 1b). Post hoc analysis ($T(1,599) = 4.51$, FWE corrected $P < .05$) confirmed increased gyrification at follow-up in the above areas and small areas of reduced gyrification in bilateral postcentral, superior parietal, and fusiform; and insula in right hemisphere.

CAPE \times TIME interaction on (dynamic) cortical gyrification was seen in right superior and inferior parietal lobules ($F(1,598) = 10.94$, $P < .001$) (figure 1c). Post-hoc independent sample t -tests for baseline and follow-up visits separately showed that high scorers had higher gyrification in these regions compared to low scorers at follow-up ($t(1,598) = 3.10$, $P < .001$) but not at baseline. This finding also survived the more stringent statistical threshold at $P < .001$ TFCE.

We performed additional analysis with the entire sample of 1252 adolescents and with CAPE-42 10th decile stratification which did not offer additional relevant information (see supplement) and both of these samples had significant confounding variables (see Table 1).

Independent Replication Sample

Demographics have been described in our previous article.⁴³ The independent sample of patients with psychosis demonstrated higher gyrification in cuneus, caudal middle frontal in the left hemisphere and lingual/fusiform, lateral occipital/cuneus and superior parietal in the right hemisphere compared to HC ($t(1,142) = 3.15$, $P < .001$).

Table 1. Demographics of the Participants

	CAPE-3		Comparison Between CAPE-3 High and Low Scorers	CAPE-42		Comparison Between CAPE-42 High and Low Scorers	Entire Sample	Correlation of CAPE Scores With Other Measures in the Entire Sample
No of participants (<i>n</i>)	600			247			1252	
Stratification	High CAPE-3	Low CAPE-3		High CAPE-42	Low CAPE-42		—	
Stratification (<i>n</i>)	313	287		123	124		1252	
Age (mean, SD) BL	14.4, 0.4	14.4, 0.4		14.4, 0.4	14.4, 0.4		14.4, 0.4	
Age (mean, SD) FU	18.9, 0.7	18.9, 0.7		18.9, 0.7	18.9, 0.7		18.9, 0.7	
Gender (M, F, NK)	127, 180, 6	160, 123, 4		39, 84, 0	69, 55, 0		591, 651, 10	
Handedness (R, L, NK)	263, 39, 11	239, 37, 11		107, 13, 3	104, 18, 2		1090, 141, 21	
WISC Verbal (mean, SD) BL	111.2, 15.4	109.6, 15.1	n.s	112.2, 15.2	106.9, 15.2	$t(df = 238) = 2.65, P = .008$	112.5, 14.7	($r = 0.10, P < .001$)
WISC performance (mean, SD) BL	108.8, 14.9	106.5, 15.3	n.s	109.5, 14.9	105.1, 14.6	$t(df = 239) = 2.29, P = .023$	108.9, 14.3	($r = 0.094, P = .001$).
ADRS (mean, SD) FU	18.1, 2.5	19.7, 0.7	($Z = 9.7, P < .001$)	16, 2.9	19.7, 0.6	($z = 11, p < 0.001$)	18.7, 2.1	($\rho = -0.492, p < 0.001$)
AUDIT (mean, SD) FU	5.9, 4.4	5.5, 4.2	n.s	7.4, 5.2	5.2, 3.7	($z = -3.35, P = .001$)	5.6, 4.1	($\rho = 0.079, P = .005$)
DAST (mean, SD) FU	1.1, 2.2	0.6, 1.2	n.s	1.7, 2.7	0.6, 1.0	($z = -2.95, P = .003$)	0.9, 1.8	($\rho = 0.097, P = .001$)

Note: n.s., not significant; Z, standardized score of nonparametric comparison; ρ , spearman correlation coefficient; r , Pearson's correlation coefficient; n , number; SD, standard deviation; BL, baseline; FU, follow-up; M, male; F, female; R, right; L, left; NK, not known; ADRS, Adolescent Depression Rating Scale; AUDIT, Alcohol Use Disorders Identification Test; CAPE-42, Community Assessment of Psychic Experiences Questionnaire, 42 items instrument; DAST, Drug Abuse Screening Test for Cannabis; WISC, Wechsler Intelligence Scale for Children.

Follow-up Diagnoses

There were 1252 adolescents included in this study, of whom 756 had follow-up data at age 23 years and of these, 16 adolescents received a diagnosis of psychosis at follow-up (2.1%). There were 12 (75%) from the high CAPE-3 group (totaling 187), and 2 (12.5%) from the low CAPE-3 group (totaling 177); and 2 (12.5%) from the remaining adolescents (intermediate CAPE-3 group). The high CAPE-3 scorers were 5.6 times more likely to develop psychosis than low CAPE-3 scorers (relative risk ratio = $(12/187)/(2/177) = 5.68$).⁴⁵ In comparison, using the CAPE-42 classification there were 6 (37.5%) that transitioned from the high CAPE-42 group, 9 (56.25%) from intermediate group and 1 (6%) from low CAPE-42 group. This supports the increased value of using the more specific CAPE-3 item scores to identify adolescents at increased risk of developing psychosis.

Discussion

Our longitudinal study presents a unique and powerful design exploring changes in gyrification during adolescence

and differentiates between *static* and *dynamic* gyrification and their association with PLEs. We show that adolescents with high PLEs, especially with experiences of voice-hearing, receiving unusual messages and persecutory ideas (CAPE-3), have lower gyrification in fronto-temporal regions that persist through mid to late adolescence compared to adolescents with low PLEs thus reflecting *static* gyrification changes. Moreover, this high PLE group displayed higher gyrification in right superior and inferior parietal cortex at follow-up where cortical gyrification in these parietal regions was also altered (higher) in an independent sample of patients with early psychosis compared to controls, thus reflecting *dynamic* gyrification changes. The utility of using the more specific CAPE items (CAPE-3) to stratify participants was supported by the observation that 75% of the 16 adolescents that transitioned to clinical psychosis at age 23 years were in the high PLE group (relative risk ratio of 5.6). Together, this suggests that the neurodevelopmental abnormalities associated with high PLEs are clinically relevant to symptoms of psychosis.

Few studies have explored gyrification as a neurodevelopmental marker for risk of developing psychosis but indicate that an early neurodevelopmental




Fig. 1. PLEs in adolescence are associated with lower fronto-temporal gyrification. (a) Differences in STATIC gyrification in fronto-temporal areas in high CAPE-3 scorers compared to low CAPE-3 scorers. (b) Changes in DYNAMIC gyrification from mid (baseline, 14 years) to late adolescence (follow-up, 19 years) reflecting maturational processes, most pronounced in prefrontal areas. (c) CAPE-3 \times TIME interaction showing changes in DYNAMIC gyrification where high CAPE-3 scorers showed higher gyrification in parietal areas at follow-up. Results reported at $P < .001$.

insult results in an earlier plateau of cortical expansion which underlies persistence of psychotic symptoms.^{16–18} However, other studies have reported both increases^{19,20} and no changes in gyrification.^{21,22} Recently, Fonville et al reported that young adults with persistent PLEs (at age 18 and 20 years) showed lower gyrification in left temporal gyrus, but relatively intact white matter, suggesting early disturbances in cortical expansion underlying vulnerability to psychosis.⁴⁶ Interestingly, Evermann et al. also showed that specific symptoms of PLEs (positive and depressive subscales) were associated with reductions in cortical gyrification in precuneus, right supramarginal, and temporal regions, but that cognition did not significantly mediate this relationship.³⁷ While these studies advanced our understanding of PLEs, most are limited by their sample size and cross-sectional design. In addition, only a few have examined changes in cortical gyrification relating to PLEs in adolescents—a crucial period of neurodevelopment and for the emergence of psychiatric disorders.

The present findings showed that adolescents with elevated CAPE-3 scores showed lower gyrification in the banks of superior temporal sulcus, middle temporal gyrus, superior frontal gyrus, and precentral gyrus in the left hemisphere; that persisted from mid-adolescence to late adolescence thus reflecting *static* gyrification changes. This is in the context of very widespread changes in cortical *dynamic* gyrification in the entire CAPE-3 group over this period, most especially in prefrontal cortices, reflecting normal maturational processes between mid-adolescence to late-adolescence. Thus, this difference in the developmental trajectory

of gyrification in the current study could reflect either a delay in this normal maturational increase, or a persistent reduction in gyrification. Lower gyrification in these areas among the higher scorers is consistent with a recent finding of lower gyrification in left temporal lobe in a cohort of young adults with persistent PLEs¹⁶ and lower cortical gyrification in schizophrenia.^{47,48} Disruption of left fronto-temporal connectivity has been associated with the genesis of positive psychotic symptoms, particularly hallucinations.^{49–51} Contemporary theories of hallucinatory experience suggest that deficits in sensory gating and language processing result in a “feedforward” aberrant information transmission leading to auditory hallucinations⁵²; deficits in salience network deficits resulting in aberrant salience that could lead to both hallucinations⁵² and delusions.⁵³ A recent cross-species study demonstrated that variation in cortical gyrification is related to underlying strength of white matter connections⁵⁴; and changes in fronto-temporal white matter connectivity has been reported to be implicated in the etiology of psychotic symptoms.⁵⁵ However, this effect was not evident in our replication study of patients with first-episode psychosis suggesting lower gyrification in these areas may reflect a marker of sub-clinical PLEs only.

We also observed a CAPE \times TIME interaction where high CAPE-3 scorers showed an increase in gyrification in the right superior and inferior parietal lobules. The parietal changes over time may reflect the specific role of the parietal cortex in efficient multimodal integration, working memory, and self-monitoring.⁵⁶ As the adolescents in our study did not have clinical intensity of

symptoms as observed in the full-blown clinical illness in schizophrenia, but were experiencing PLEs, it is possible that these increases in gyrification in the inferior parietal lobule may reflect compensatory mechanisms supplementary to the more widely observed age-related maturational changes and hence changes in *dynamic gyrification*. This compensatory increase in gyrification may be secondary to lower fronto-temporal gyrification in high PLE adolescents that may reflect the consequent need for enhanced self-monitoring of self-generated material—a function of the left superior temporal gyrus that is often disrupted in psychotic patients.^{49–51} Indeed, this compensatory increase in gyrification is supported by data demonstrating higher parietal cortical gyrification in healthy adults was associated with better functional capacity⁵⁷ while it was associated with persistent auditory hallucinations in schizophrenia.⁵⁸ In addition, we observed higher gyrification in right parietal cortex in our independent sample of patients with first-episode psychosis compared to HC, thus replicating the changes of *dynamic gyrification*. This suggests a potential compensatory mechanism that spans across high-risk and clinical populations, supporting similar structural changes across a spectrum of psychotic experience. It is recognized that development during adolescence involves significant structural brain changes and cortical gyrification which may be influenced by underlying changes in gray matter volume, white matter integrity, brain volume, and surface area,^{59–61} referred to as *dynamic gyrification*. The changes in *dynamic gyrification* in parietal cortex which appears at late adolescence and also seen in those with first-episode psychosis may therefore reflect changes in shape and curvature related to cortical morphology/white matter pathology. It is known that persistent PLEs increase the risk of transition to psychosis,^{7–10} a finding that is replicated here (high CAPE-3 scorers were 5.6 times more likely to transition to psychosis than low CAPE-3 scorers). These abnormalities in developmental trajectory of gyrification may therefore underlie PLEs in adolescents and provide a structural marker for vulnerability to psychosis.

The exploratory stratification using the entire CAPE-42 replicated the higher gyrification in right superior parietal lobule but not the persistent reduction in gyrification as seen in the CAPE-3 high scorers. Of interest, although there was a strong correlation between CAPE-3 and CAPE-42 scores, and both were based on the same threshold on the positive subscale, our study indicates that stratification by CAPE-3 scores isolates a different subset of adolescents than when stratified by CAPE-42 scores. Indeed, there were no correlations between total CAPE-42 score and gyrification in the total sample and fewer adolescents that transitioned to psychosis were classified as experiencing high PLEs using the CAPE-42. This is not surprising because the CAPE 42 indexes a very broad range of experiences, with an increased number of nonspecific symptoms, while the

CAPE-3 is focused on specific symptoms most proximal to clinical symptoms observed in psychotic illness. In our study, the high CAPE-3 scoring sample was not different on any confounding factors such as IQ, alcohol, or cannabis use. However, sub-clinical depressive symptoms (ADRS scores) were higher in the high versus low CAPE-3 scorers. Our data therefore support the value in stratifying adolescents according to CAPE-3 item scores and suggests that changes in gyrification are specific to these positive symptoms.

Limitations

First, PLEs, depression, and substance-use measures were available only at follow-up (age 19 years). It is unclear if some adolescents experienced PLEs at baseline or whether the lower gyrification in fronto-temporal regions contributed to PLEs at follow-up. The high and low CAPE-3 groups were relatively well matched for all key variables except for depressive symptoms. Additionally, although the main findings in the study relating to the CAPE-3 cohort are confirmed using robust non-parametric permutation methods (TFCE), most of the results are reported at a liberal statistical threshold ($P < .001$ uncorrected). This limitation may be a result of small effect sizes in cortical gyrification studies, heterogeneity between adolescents, and CAPE scores that were only measured at age 19 years follow-up—this reflects the difficulties in studying PLEs. Moreover, our analyses investigating transition to psychosis were restricted to the adolescents that were followed up at age 23 years. Although the percentage drop-out was similar between high (40% decrease) and low (38% decrease) CAPE-3 scorers, the large drop-out introduces (unavoidable) bias to the sample as the reasons for drop-out are unclear and may reflect worsening PLEs or other mental health issues. Future studies aiming to replicate the current findings are therefore needed. Finally, due to careful harmonization procedures conducted in advance between scanning sites, scanning site was controlled for in analyses using a commonly used regression approach to remove mean differences between sites. However more sophisticated harmonization procedures could be considered in future.

Conclusion

Our study demonstrates that adolescents with PLEs show increased rates of transition to psychosis accompanied by a neurodevelopmental brain structural abnormality of lower gyrification in fronto-temporal regions in the left hemisphere and increased gyrification in parietal regions in the right hemisphere. This was particularly in relation to positive PLEs such as hearing voices, bizarre experiences, and persecutory ideas, instead of negative PLEs such as blunted emotions. These neurodevelopmental abnormalities, especially in parietal cortex, are relevant to

the clinical symptoms of psychosis and could offer a biomarker for identifying adolescents at high risk of transitioning to psychosis.

Supplementary Material

Supplementary material is available at <https://academic.oup.com/schizophreniabulletin/>.

Acknowledgments

We are sincerely grateful to our collaborators in the IMAGEN consortium and our funding bodies.

Funding

This work received support from the following sources: the European Union-funded FP6 Integrated Project IMAGEN (Reinforcement-related behaviour in normal brain function and psychopathology) (LSHM-CT-2007-037286), the Horizon 2020 funded ERC Advanced Grant 'STRATIFY' (Brain network based stratification of reinforcement-related disorders) (695313), Human Brain Project (HBP SGA 2, 785907, and HBP SGA 3, 945539), the Medical Research Council Grant 'c-VEDA' (Consortium on Vulnerability to Externalizing Disorders and Addictions) (MR/N000390/1), the National Institute of Health (NIH) (R01DA049238, A decentralized macro and micro gene-by-environment interaction analysis of substance use behavior and its brain biomarkers), the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, the Bundesministerium für Bildung und Forschung (BMBF grants 01GS08152; 01EV0711; Forschungsnetz AERIAL 01EE1406A, 01EE1406B; Forschungsnetz IMAC-Mind 01GL1745B), the Deutsche Forschungsgemeinschaft (DFG grants SM 80/7-2, SFB 940, TRR 265, NE 1383/14-1), the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy – EXC-2049 – 390688087, the Medical Research Foundation and Medical Research Council (grants MR/R00465X/1 and MR/S020306/1), the National Institutes of Health (NIH) funded ENIGMA (grants 5U54EB020403-05 and 1R56AG058854-01). Further support was provided by grants from: - the ANR (ANR-12-SAMA-0004, AAPG2019 - GeBra), the Eranet Neuron (AF12-NEUR0008-01 - WM2NA; and ANR-18-NEUR00002-01 - ADORe), the Fondation de France (00081242), the Fondation pour la Recherche Médicale (DPA20140629802), the Mission Interministérielle de Lutte-contre-les-Drogues-et-les-Conduites-Addictives (MILDECA), the Assistance-Publique-Hôpitaux-de-Paris and INSERM (interface grant), Paris Sud University IDEX 2012, the Fondation de l'Avenir (grant

AP-RM-17-013), the Fédération pour la Recherche sur le Cerveau; the National Institutes of Health, Science Foundation Ireland (16/ERC/3797), USA (Axon, Testosterone and Mental Health during Adolescence; RO1 MH085772-01A1), and by NIH Consortium grant U54 EB020403, supported by a cross-NIH alliance that funds Big Data to Knowledge Centres of Excellence, the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust (SLaM) and King's College London (KCL).

Conflict of Interest

Dr Banaschewski served in an advisory or consultancy role for ADHS digital, Infectopharm, Lundbeck, Medice, Neurim Pharmaceuticals, Oberberg GmbH, Roche, and Takeda. He received conference support or speaker's fee by Medice and Takeda. He received royalties from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press; the present work is unrelated to these relationships. Dr Barker has received honoraria from General Electric Healthcare for teaching on scanner programming courses. Dr Poustka served in an advisory or consultancy role for Roche and Viforpharm and received speaker's fee by Shire. She received royalties from Hogrefe, Kohlhammer and Schattauer. Dr Papanastasiou is an employee of Boehringer Ingelheim; the present work is unrelated to this relationship. The present work is unrelated to the above grants and relationships. The other authors report no biomedical financial interests or potential conflicts of interest.

References

1. Hinterbuchinger B, Mossaheb N. Psychotic-like experiences: a challenge in definition and assessment. *Front Psychiatry*. 2021;12:582392.
2. Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. *JAMA Psychiatry*. 2013;70(1):107–120.
3. Pain O, Dudbridge F, Cardno AG, et al. Genome-wide analysis of adolescent psychotic-like experiences shows genetic overlap with psychiatric disorders. *Am J Med Genet*. 2018;177(4):416–425.
4. Mackie CJ, Castellanos-Ryan N, Conrod PJ. Developmental trajectories of psychotic-like experiences across adolescence: impact of victimization and substance use. *Psychol Med*. 2011;41(1):47–58.
5. Kelleher I, Connor D, Clarke MC, Devlin N, Harley M, Cannon M. Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. *Psychol Med*. 2012;42(9):1857–1863.
6. Kelleher I, Keeley H, Corcoran P, et al. Clinicopathological significance of psychotic experiences in non-psychotic young people: evidence from four population-based studies. *Br J Psychiatry*. 2012;201(1):26–32.

7. Poulton R, Caspi A, Moffitt TE, Cannon M, Murray R, Harrington H. Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. *Arch Gen Psychiatry*. 2000;57(11):1053–1058.
8. Scott J, Martin G, Welham J, *et al*. Psychopathology during childhood and adolescence predicts delusional-like experiences in adults: a 21-year birth cohort study. *Am J Psychiatry*. 2009;166(5):567–574.
9. Welham J, Scott J, Williams G, *et al*. Emotional and behavioural antecedents of young adults who screen positive for non-affective psychosis: a 21-year birth cohort study. *Psychol Med*. 2009;39(4):625–634.
10. Kaymaz N, Drukker M, Lieb R, *et al*. Do subthreshold psychotic experiences predict clinical outcomes in unselected non-help-seeking population-based samples? A systematic review and meta-analysis, enriched with new results. *Psychol Med*. 2012;42(11):2239–2253.
11. DeRosse P, Ikuta T, Karlsgodt KH, *et al*. White matter abnormalities associated with subsyndromal psychotic-like symptoms predict later social competence in children and adolescents. *Schizophr Bull*. 2017;43(1):152–159.
12. Drakesmith M, Dutt A, Fonville L, *et al*. Mediation of developmental risk factors for psychosis by white matter microstructure in young adults with psychotic experiences. *JAMA Psychiatry*. 2016;73(4):396–406.
13. Nesvag R, Reichborn-Kjennerud T, Gillespie NA, *et al*. Genetic and environmental contributions to the association between cannabis use and psychotic-like experiences in young adult twins. *Schizophr Bull*. 2017;43(3):644–653.
14. Armstrong E, Schleicher A, Omran H, Curtis M, Zilles K. The ontogeny of human gyrification. *Cereb Cortex*. 1995;5(1):56–63.
15. Zilles K, Armstrong E, Schleicher A, Kretschmann HJ. The human pattern of gyrification in the cerebral cortex. *Anat Embryol (Berl)*. 1988;179(2):173–179.
16. Fonville L, Drakesmith M, Zammit S, Lewis G, Jones DK, David AS. MRI indices of cortical development in young people with psychotic experiences: influence of genetic risk and persistence of symptoms. *Schizophr Bull*. 2019;45(1):169–179.
17. de Wit S, Ziermans TB, Nieuwenhuis M, *et al*. Individual prediction of long-term outcome in adolescents at ultra-high risk for psychosis: applying machine learning techniques to brain imaging data. *Hum Brain Mapp*. 2017;38(2):704–714.
18. Damme KSF, Gupta T, Nusslock R, Bernard JA, Orr JM, Mittal VA. Cortical morphometry in the psychosis risk period: a comprehensive perspective of surface features. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2019;4(5):434–443.
19. Harris JM, Whalley H, Yates S, Miller P, Johnstone EC, Lawrie SM. Abnormal cortical folding in high-risk individuals: a predictor of the development of schizophrenia? *Biol Psychiatry*. 2004;56(3):182–189.
20. Sasabayashi D, Takayanagi Y, Takahashi T, *et al*. Increased occipital gyrification and development of psychotic disorders in individuals with an at-risk mental state: a multicenter study. *Biol Psychiatry*. 2017;82(10):737–745.
21. Bakker G, Caan MW, Vingerhoets WA, *et al*. Cortical morphology differences in subjects at increased vulnerability for developing a psychotic disorder: a comparison between subjects with ultra-high risk and 22q11.2 deletion syndrome. *PLoS One*. 2016;11(11):e0159928.
22. Padula MC, Schaer M, Armando M, *et al*. Cortical morphology development in patients with 22q11.2 deletion syndrome at ultra-high risk of psychosis. *Psychol Med*. 2018;48(14):2375–2383.
23. Matsuda Y, Ohi K. Cortical gyrification in schizophrenia: current perspectives. *Neuropsychiatr Dis Treat*. 2018;14:1861–1869.
24. Sasabayashi D, Takahashi T, Takayanagi Y, Suzuki M. Anomalous brain gyrification patterns in major psychiatric disorders: a systematic review and transdiagnostic integration. *Transl Psychiatry*. 2021;11(1):176.
25. Welcome to the IMAGEN Study. <https://imagen-europe.com/>. Accessed January 1, 2018.
26. Mossaheb N, Becker J, Schaefer MR, *et al*. The Community Assessment of Psychic Experience (CAPE) questionnaire as a screening-instrument in the detection of individuals at ultra-high risk for psychosis. *Schizophr Res*. 2012;141(2-3):210–214.
27. Konings M, Bak M, Hanssen M, van Os J, Krabbendam L. Validity and reliability of the CAPE: a self-report instrument for the measurement of psychotic experiences in the general population. *Acta Psychiatr Scand*. 2006;114(1):55–61.
28. Mark W, Touloupoulou T. Psychometric properties of “community assessment of psychic experiences”: review and meta-analyses. *Schizophr Bull*. 2016;42(1):34–44.
29. Yung AR, Nelson B, Baker K, Buckby JA, Baksheev G, Cosgrave EM. Psychotic-like experiences in a community sample of adolescents: implications for the continuum model of psychosis and prediction of schizophrenia. *Aust N Z J Psychiatry*. 2009;43(2):118–128.
30. Wechsler D. *Wechsler Intelligence Scale for Children*. 4th ed. San Antonio, TX: Psychological Corporation; 2003.
31. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption--II. *Addiction*. 1993;88(6):791–804.
32. Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. *J Stud Alcohol*. 1995;56(4):423–432.
33. Skinner HA. The drug abuse screening test. *Addict Behav*. 1982;7(4):363–371.
34. Revah-Levy A, Birmaher B, Gasquet I, Falissard B. The Adolescent Depression Rating Scale (ADRS): a validation study. *BMC Psychiatry*. 2007;7(1):2.
35. Schumann G, Loth E, Banaschewski T, *et al*. The IMAGEN study: reinforcement-related behaviour in normal brain function and psychopathology. *Mol Psychiatry*. 2010;15:1128–1139.
36. Luders E, Thompson PM, Narr KL, Toga AW, Jancke L, Gaser C. A curvature-based approach to estimate local gyrification on the cortical surface. *Neuroimage*. 2006;29(4):1224–1230.
37. Evermann U, Gaser C, Besteher B, Langbein K, Nenadić I. Cortical gyrification, psychotic-like experiences, and cognitive performance in nonclinical subjects. *Schizophr Bull*. 2020;46(6):1524–1534.
38. Desikan RS, Segonne F, Fischl B, *et al*. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *Neuroimage*. 2006;31(3):968–980.
39. IBM. *IBM SPSS Statistics for Macintosh. Version 25.0 ed*. Armonk, NY: IBM Corp.; 2017.
40. Caverzasi E, Battistella G, Chu SA, *et al*. Gyrification abnormalities in presymptomatic c9orf72 expansion carriers. *J Neurol Neurosurg Psychiatry*. 2019;90(9):1005–1010.

41. Lee SE, Sias AC, Mandelli ML, *et al.* Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. *Neuroimage Clin.* 2017;14:286–297.
42. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. *Neuroimage.* 2009;44(1):83–98.
43. Thomas M, Szentgyorgyi T, Vanes LD, *et al.* Cognitive performance in early, treatment-resistant psychosis patients: could cognitive control play a role in persistent symptoms? *Psychiatry Res.* 2021;295:113607.
44. Sheehan DV, Lecrubier Y, Sheehan KH, *et al.* The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry.* 1998;59:22–33;quiz 34.
45. Andrade C. Understanding relative risk, odds ratio, and related terms: as simple as it can get. *J Clin Psychiatry.* 2015;76(7):e857–e861.
46. Fonville L, Drakesmith M, Zammit S, Lewis G, Jones DK, David AS. MRI indices of cortical development in young people with psychotic experiences: influence of genetic risk and persistence of symptoms. *Schizophr Bull.* 2019;45(1):169–179.
47. White T, Hilgetag CC. Gyrification and neural connectivity in schizophrenia. *Dev Psychopathol.* 2011;23(1):339–352.
48. Cao B, Mwangi B, Passos IC, *et al.* Lifespan gyrification trajectories of human brain in healthy individuals and patients with major psychiatric disorders. *Sci Rep.* 2017;7(1):511.
49. Simons CJ, Tracy DK, Sanghera KK, *et al.* Functional magnetic resonance imaging of inner speech in schizophrenia. *Biol Psychiatry.* 2010;67(3):232–237.
50. Shergill SS, Brammer MJ, Fukuda R, Williams SC, Murray RM, McGuire PK. Engagement of brain areas implicated in processing inner speech in people with auditory hallucinations. *Br J Psychiatry.* 2003;182:525–531.
51. Shergill SS, Brammer MJ, Fukuda R, *et al.* Modulation of activity in temporal cortex during generation of inner speech. *Hum Brain Mapp.* 2002;16(4):219–227.
52. Tracy DK, Shergill SS. Mechanisms underlying auditory hallucinations-understanding perception without stimulus. *Brain Sci.* 2013;3(2):642–669.
53. So SH, Chau AKC, iPeters ER, Swendsen J, Garety PA, Kapur S. Moment-to-moment associations between negative affect, aberrant salience, and paranoia. *Cogn Neuropsychiatry.* 2018;23(5):299–306.
54. Van Essen DC, Donahue CJ, Coalson TS, Kennedy H, Hayashi T, Glasser MF. Cerebral cortical folding, parcellation, and connectivity in humans, nonhuman primates, and mice. *Proc Natl Acad Sci USA.* 2019;116(52):26173–26180.
55. Jones DK, Catani M, Pierpaoli C, *et al.* Age effects on diffusion tensor magnetic resonance imaging tractography measures of frontal cortex connections in schizophrenia. *Hum Brain Mapp.* 2006;27(3):230–238.
56. Ribolsi M, Lisi G, Di Lorenzo G, *et al.* Perceptual pseudoneglect in schizophrenia: candidate endophenotype and the role of the right parietal cortex. *Schizophr Bull.* 2013;39(3):601–607.
57. Green S, Blackmon K, Thesen T, *et al.* Parieto-frontal gyrification and working memory in healthy adults. *Brain Imaging Behav.* 2018;12(2):303–308.
58. Kubera KM, Thomann PA, Hirjak D, *et al.* Cortical folding abnormalities in patients with schizophrenia who have persistent auditory verbal hallucinations. *Eur Neuropsychopharmacol.* 2018;28(2):297–306.
59. Gautam P, Anstey KJ, Wen W, Sachdev PS, Cherbuin N. Cortical gyrification and its relationships with cortical volume, cortical thickness, and cognitive performance in healthy mid-life adults. *Behav Brain Res.* 2015;287:331–339.
60. Schultz CC, Wagner G, Schachtzabel C, *et al.* Increased white matter radial diffusivity is associated with prefrontal cortical folding deficits in schizophrenia. *Psychiatry Res Neuroimaging.* 2017;261:91–95.
61. Toro R, Perron M, Pike B, *et al.* Brain size and folding of the human cerebral cortex. *Cereb Cortex.* 2008;18(10):2352–2357.